Given these results, AR suppressive agents have been tested either alone or in combination with other drugs in clinical trials in patients with ERα-negative BrCa and have shown efficacy in some patients [105,106,107], but these malignancies are aggressive, and patients who respond quickly relapse [108]. This evidence concerns the gene ESR1 and invasive breast carcinoma.